{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:05:13Z","timestamp":1767834313637,"version":"3.49.0"},"reference-count":39,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJOG"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:p><jats:bold>Objective\u2002<\/jats:bold> To assess the potential epidemiological and economic impact of a prophylactic quadrivalent human papillomavirus (HPV) (6\/11\/16\/18) vaccine for preventing cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN2\/3), CIN1 and genital warts.<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> Cost\u2010utility analysis.<\/jats:p><jats:p><jats:bold>Setting\u2002<\/jats:bold> UK.<\/jats:p><jats:p><jats:bold>Population\u2002<\/jats:bold> Female and male UK population 12 years or older.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> We adapted a previously developed multi\u2010HPV type dynamic transmission to compare four female vaccination strategies, routine vaccination at age 12 years, and routine vaccination at age 12 years combined with temporary catch\u2010up vaccination at ages 12\u201314, 12\u201317 and 12\u201324 years.<\/jats:p><jats:p><jats:bold>Main outcomes measures\u2002<\/jats:bold> Costs, cases avoided, incremental cost per quality\u2010adjusted life year (QALY).<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> The model projected that at year 100, each vaccination strategy could reduce the number of HPV 6\/11\/16\/18\u2010related cervical cancer, CIN2\/3, CIN1 and genital wart cases among women by 86, 85, 79 and 89% respectively. Over 25 years, routine vaccination at age 12 years combined with a 12\u2010 to 24\u2010year\u2010old catch\u2010up programme was the most effective strategy, reducing the cumulative number of cases of cervical cancer, CIN2\/3, CIN1 and genital warts by 5800, 146\u2003000, 28\u2003000, and 1.1 million respectively. Over 100 years, the incremental cost\u2010effectiveness ratios across all strategies ranged from \u00a35882 to \u00a311,412 per QALY gained.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> In the UK, a quadrivalent HPV vaccination programme that includes a catch\u2010up strategy can reduce the incidence of cervical cancer, CIN and genital warts at a cost per QALY ratio within the range typically regarded as cost\u2010effective.<\/jats:p>","DOI":"10.1111\/j.1471-0528.2008.01743.x","type":"journal-article","created":{"date-parts":[[2008,5,23]],"date-time":"2008-05-23T10:49:02Z","timestamp":1211539742000},"page":"947-956","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6\/11\/16\/18) in the UK"],"prefix":"10.1111","volume":"115","author":[{"given":"EJ","family":"Dasbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RP","family":"Insinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EH","family":"Elbasha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_9_2_2","unstructured":"European Agency for the Evaluation of Medicinal Products (EMEA).European Public Assessment Report (EPAR). London UK:EMEA.2006[www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/gardasil\/H\u2010703\u2010PI\u2010en.pdf]. Accessed 30 November 2007."},{"key":"e_1_2_9_3_2","unstructured":"Sanofi Pasteur MSD.Gardasil: the vaccine that can prevent cervical cancer approved for use in the European Union. Lyon France:Sanofi Pasteur MSD.2006[www.spmsd.com\/press\/Gardasil%20AMM%20\u2010%20english%20press%20release%20accord%20dif\u2010%20220906.pdf]. Accessed 30 November 2007."},{"key":"e_1_2_9_4_2","volume-title":"Development of Recommendations for HPV Vaccine Use in the United States","author":"Markowitz L","year":"2005"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/epirev\/mxj006"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1301.060438"},{"key":"e_1_2_9_7_2","unstructured":"Department of Health (National).HPV Vaccine Recommended for NHS Immunisation Programme.Government News Network 2007[www.gnn.gov.uk\/environment\/fullDetail.asp?ReleaseID=325799&NewsAreaID=2]."},{"key":"e_1_2_9_8_2","unstructured":"National Health Service (NHS) Cervical Screening Programme Statistics.Cervical Cancer Screening Program [2005\/2006]. Leeds UK:The Information Centre 2006[www.ic.nhs.uk\/pubs\/csp0506]. Accessed 30 November 2007."},{"key":"e_1_2_9_9_2","unstructured":"ErensB McManusS PrescottP FieldJ JohnsonA WellingsK et al.National Survey of Sexual Attitudes and Lifestyles II: Reference Tables and Summary Report Table 3.17.National Centre for Social Research 2002[www.natcen.ac.uk\/natsal\/reference_tables.doc]."},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1258\/0956462041558168"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta8200"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601884"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X07302128"},{"key":"e_1_2_9_14_2","volume-title":"Patient Preferences for Health States Related to HPV Infection: Visual Analogue Scales vs Time Trade\u2010Off Elicitation","author":"Myers ER","year":"2004"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70101-7"},{"key":"e_1_2_9_16_2","first-page":"318","article-title":"Universal hepatitis B vaccination of UK adolescents: a feasibility and acceptability study","volume":"5","author":"Bramley JC","year":"2002","journal-title":"Commun Dis Public Health"},{"key":"e_1_2_9_17_2","doi-asserted-by":"crossref","unstructured":"TrotterCL EdmundsWJ RamsayME MillerE.Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales.Hum Vaccin2006;2:68\u201373[www.nice.org.uk\/page.aspx?o=201973].","DOI":"10.4161\/hv.2.2.2611"},{"key":"e_1_2_9_18_2","volume-title":"Guide to the Methods of Technology Appraisal, May 2004","author":"National Institute for Clinical Excellence (NICE)","year":"2007"},{"key":"e_1_2_9_19_2","doi-asserted-by":"crossref","unstructured":"ElbashaEH GalvaniAP.Vaccination against multiple HPV types.Math Biosci2005;197:88\u2013117.","DOI":"10.1016\/j.mbs.2005.05.004"},{"key":"e_1_2_9_20_2","unstructured":"ChessonH.The Potential Cost\u2010Effectiveness of HPV Vaccination in the United States: a review of published and ongoing studies.Advisory Committee on Immunization PracticesJune 29 2006. Altlanta GA USA:Centers for Disease Control and Prevention [www.cdc.gov\/vaccines\/recs\/acip\/downloads\/min\u2010jun06.pdf]. Accessed 30 November 2007."},{"key":"e_1_2_9_21_2","unstructured":"Office of National Statistics (ONS).Office for National Statistics. Cancer Statistics Registrations: Registrations of Cancer Diagnosed in 2004 England. Series MB1 no. 34. London UK:Cancer Research UK.2007[www.info.cancerresearchuk.org\/cancerstats\/types\/cervix\/incidence\/]. Accessed 30 November 2007."},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20244"},{"key":"e_1_2_9_23_2","unstructured":"Health Protection Agency (HPA).Diagnoses and Rates of Selected STIs Seen at GUM Clinics United Kingdom: 2000\u20132004. National Regional and Strategic Health Authority Summary Tables. London UK:HPA.2005[www.hpa.org.uk\/infections\/topics_az\/hiv_and_sti\/epidemiology\/datatables2004.htm]. Accessed 30 November 2007."},{"key":"e_1_2_9_24_2","first-page":"450","article-title":"Changes in HPV infection in patients with anogenital warts and their partners","volume":"69","author":"Hillman RJ","year":"1993","journal-title":"Genitourin Med"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ogx.0000221010.82943.8c"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X02239651"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/62.1.187"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/427557"},{"key":"e_1_2_9_29_2","unstructured":"Center on the Evaluation of Value and Risk in Health.The Cost\u2010Effectiveness Analysis Registry. Boston MA USA:Tufts\u2010New England Medical Center ICRHPS Geneva Switzerland:WHO.2006[www.tufts\u2010nemc.org\/cearegistry\/data\/docs\/PhaseIIIACompleteLeagueTable.pdf]. Accessed 30 November 2007."},{"key":"e_1_2_9_30_2","unstructured":"World Health Organization (WHO).Tables of costs and prices used in WHO\u2010CHOICE analysis.2007[www.who.int\/choice\/costs\/CER_levels\/en\/index.html]. Accessed 30 November 2007."},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/hec.864"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603469"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19991215)18:23<3263::AID-SIM315>3.0.CO;2-3"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603501"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60777-6"},{"key":"e_1_2_9_36_2","unstructured":"Merck & Co.Merck Submits New Cross\u2010Protection Data for Gardasil\u00aeto the FDA and Seeks New Indications for Vaginal and Vulvar Cancers. Whitehouse Station NJ USA:Merck & Co.2007[www.merck.com\/newsroom\/press_releases\/product\/2007_0417.html]. Accessed 30 November 2007."},{"key":"e_1_2_9_37_2","unstructured":"HauptRM.GARDASIL Update: End of Study (16\u201326 Year Olds) Adult Women (24\u201345 Year Olds). Atlanta GA USA:Centers for Disease Control and Prevention. 2\u201027\u20100008.Centers for Disease Control and Prevention\/Advisory Committee on Immunization Practices. [www.cdc.gov\/vaccines\/recs\/acip\/meetings.htm#min]. Accessed 5 March 2008."},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1086\/520654"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.11.1460"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00232-9"}],"container-title":["BJOG: An International Journal of Obstetrics &amp; Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1471-0528.2008.01743.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1471-0528.2008.01743.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T13:28:02Z","timestamp":1697376482000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/j.1471-0528.2008.01743.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,28]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1111\/j.1471-0528.2008.01743.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1471-0528.2008.01743.x","archive":["Portico"],"relation":{},"ISSN":["1470-0328","1471-0528"],"issn-type":[{"value":"1470-0328","type":"print"},{"value":"1471-0528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,28]]},"assertion":[{"value":"2008-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}